HBW-012336

Primary objectives: (1) To evaluate the safety and tolerability of HBW-012336 in patients with locally advanced or metastatic solid tumors carrying KRAS G12D mutations, explore the MTD of HBW-012336, and recommend a reasonable dosing regimen (RP2D) for Phase II clinical studies. Secondary objectives: (1) To evaluate the PK characteristics of HBW-012336 in patients with locally advanced or metastatic solid tumors carrying KRAS G12D mutations; (2) To preliminarily evaluate the anti-tumor efficacy of HBW-012336 in patients with locally advanced or metastatic solid tumors carrying KRAS G12D mutations.